miRNA in Chronic Kidney Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MicroRNAs in Acute Kidney Injury

NCT03089242

Kidney Injury in Cardiac Surgery - Expression of microRNAs

COMPLETED

Acute Physiological Response to Exercise in End Stage Renal Disease

NCT03064555

Renal Disease

COMPLETED

Skeletal Muscle Oxygenation in Patients With Chronic Kidney Disease Stage 2, 3 and 4

NCT05250167

Chronic Kidney Diseases

COMPLETED

Circulating lncRNA and CV Morbidities in CKD and ESRD

NCT02304471

Chronic Kidney Disease End-stage Renal Disease

UNKNOWN

Role of Chronic Kidney Disease in Cardiovascular Disease

NCT00069810

Cardiovascular Diseases Heart Diseases Kidney Failure, Chronic

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic kidney disease group

Patients with stage 3-5 CKD (eGFR CKD-EPI \<60 mL/min/1.73 m2)

No interventions assigned to this group

Healthy controls

Healthy normotensive patients (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg)

No interventions assigned to this group

Hypertensive Group

Hypertensive patients without CKD (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy normotensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg)
* hypertensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg)
* patients with chronic kidney disease stage 3-5 (eGFR CKD-EPI\< 60 mL/min/1.73 m2)